Insulin intranasal - Aegis Therapeutics

Drug Profile

Insulin intranasal - Aegis Therapeutics

Alternative Names: Insulin Nasal Spray - Aegis Therapeutics; Shirt pocket insulin - Aegis

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aegis Therapeutics LLC
  • Developer Aegis Therapeutics
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (Intranasal, Spray)
  • 15 Jul 2014 Insulin intranasal - Aegis Therapeutics is available for licensing in Asia, North America, European Union, Middle East as of 15 Jul 2014. http://aegisthera.com
  • 24 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top